Press release
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Allergic Conjunctivitis pipeline constitutes 22+ key companies continuously working towards developing 22+ Allergic Conjunctivitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Allergic Conjunctivitis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Allergic Conjunctivitis Market.
The Allergic Conjunctivitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Allergic Conjunctivitis Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Allergic Conjunctivitis treatment therapies with a considerable amount of success over the years.
*
Allergic Conjunctivitis companies working in the treatment market are OKYO Pharma, IACTA Pharmaceuticals, VANDA PHARMACEUTICALS, Bausch & Lomb Incorporated, Aldeyra Therapeutics, Inc, Ocular Therapeutix, and others, are developing therapies for the Allergic Conjunctivitis treatment
*
Emerging Allergic Conjunctivitis therapies in the different phases of clinical trials are- OK-101, IC-270, VSJ-110, Brimonidine Tartrate, Reproxalap, Ketotifen fumarate ophthalmic solution, Dextenza, and others are expected to have a significant impact on the Allergic Conjunctivitis market in the coming years.
*
In April 2025, Ocular Therapeutix, Inc. announced the results of a randomized, parallel-arm, active-controlled, multi-center study evaluating the safety and efficacy of Dextenza Registered for treating ocular pain and inflammation after surgery for pediatric cataract.
*
In March 2025, Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval from the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), which the FDA has determined to be bioequivalent to Pataday Registered Once Daily Relief Ophthalmic Solution, 0.2% (OTC), by Alcon Laboratories, Inc. Glenmark Therapeutics Inc., USA, will distribute Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) in the U.S. market.
*
In August 2024, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company focused on developing innovative treatments for immune-mediated and metabolic diseases, announced the successful achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled clinical trial of 0.25% reproxalap ophthalmic solution, an investigational drug for treating dry eye disease. Reproxalap demonstrated statistically significant superiority over the vehicle in reducing ocular discomfort (P=0.004), a symptom of dry eye disease recognized by the U.S. Food and Drug Administration (FDA).
Allergic Conjunctivitis Overview
Allergic conjunctivitis is an eye condition characterized by inflammation of the conjunctiva, which is the thin, transparent layer of tissue covering the front surface of the eye and the inner surface of the eyelids. It occurs as a result of an allergic reaction, triggered by exposure to allergens such as pollen, dust mites, pet dander, or certain irritants like smoke or perfume.
Get a Free Sample PDF Report to know more about Allergic Conjunctivitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/allergic-conjunctivitis-pipeline-insight [https://www.delveinsight.com/report-store/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Allergic Conjunctivitis Drugs Under Different Phases of Clinical Development Include:
*
OK-101: OKYO Pharma
*
IC-270: IACTA Pharmaceuticals
*
VSJ-110: VANDA PHARMACEUTICALS
*
Brimonidine Tartrate/KetotifenFumarate: Bausch & Lomb Incorporated
*
Reproxalap: Aldeyra Therapeutics, Inc
*
Ketotifen fumarate ophthalmic solution: Bausch & Lomb Incorporated
*
Dextenza: Ocular Therapeutix
Allergic Conjunctivitis Route of Administration
Allergic Conjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Inhalation
*
Inhalation/Intravenous/Oral
*
Intranasal
*
Intravenous
*
Intravenous/ Subcutaneous
*
NA
*
Oral
*
Oral/intranasal/subcutaneous
*
Parenteral
*
Subcutaneous
Allergic Conjunctivitis Molecule Type
Allergic Conjunctivitis Products have been categorized under various Molecule types, such as
*
Antibody
*
Antisense oligonucleotides
*
Immunotherapy
*
Monoclonal antibody
*
Peptides
*
Protein
*
Recombinant protein
*
Small molecule
*
Stem Cell
*
Vaccine
Allergic Conjunctivitis Pipeline Therapeutics Assessment
*
Allergic Conjunctivitis Assessment by Product Type
*
Allergic Conjunctivitis By Stage and Product Type
*
Allergic Conjunctivitis Assessment by Route of Administration
*
Allergic Conjunctivitis By Stage and Route of Administration
*
Allergic Conjunctivitis Assessment by Molecule Type
*
Allergic Conjunctivitis by Stage and Molecule Type
DelveInsight's Allergic Conjunctivitis Report covers around 22+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Allergic Conjunctivitis product details are provided in the report. Download the Allergic Conjunctivitis pipeline report to learn more about the emerging Allergic Conjunctivitis therapies [https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Allergic Conjunctivitis Therapeutics Market include:
Key companies developing therapies for Allergic Conjunctivitis are - OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Bausch & Lomb Incorporated, Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, and others.
Allergic Conjunctivitis Pipeline Analysis:
The Allergic Conjunctivitis pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Allergic Conjunctivitis with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Allergic Conjunctivitis Treatment.
*
Allergic Conjunctivitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Allergic Conjunctivitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Allergic Conjunctivitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Allergic Conjunctivitis drugs and therapies [https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Allergic Conjunctivitis Pipeline Market Drivers
*
Increased Prevalence of Allergic Conjunctivitis, recent Advancements in Research and Developmental Activities are some of the important factors that are fueling the Allergic Conjunctivitis Market.
Allergic Conjunctivitis Pipeline Market Barriers
*
However, lack of awareness of the Disease Condition, adverse effects of the current treatment options and other factors are creating obstacles in the Allergic Conjunctivitis Market growth.
Scope of Allergic Conjunctivitis Pipeline Drug Insight
*
Coverage: Global
*
Key Allergic Conjunctivitis Companies: OKYO Pharma, IACTA Pharmaceuticals, VANDA PHARMACEUTICALS, Bausch & Lomb Incorporated, Aldeyra Therapeutics, Inc, Ocular Therapeutix, and others
*
Key Allergic Conjunctivitis Therapies: OK-101, IC-270, VSJ-110, Brimonidine Tartrate, Reproxalap, Ketotifen fumarate ophthalmic solution, Dextenza, and others
*
Allergic Conjunctivitis Therapeutic Assessment: Allergic Conjunctivitis current marketed and Allergic Conjunctivitis emerging therapies
*
Allergic Conjunctivitis Market Dynamics: Allergic Conjunctivitis market drivers and Allergic Conjunctivitis market barriers
Request for Sample PDF Report for Allergic Conjunctivitis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Allergic Conjunctivitis Report Introduction
2. Allergic Conjunctivitis Executive Summary
3. Allergic Conjunctivitis Overview
4. Allergic Conjunctivitis- Analytical Perspective In-depth Commercial Assessment
5. Allergic Conjunctivitis Pipeline Therapeutics
6. Allergic Conjunctivitis Late Stage Products (Phase II/III)
7. Allergic Conjunctivitis Mid Stage Products (Phase II)
8. Allergic Conjunctivitis Early Stage Products (Phase I)
9. Allergic Conjunctivitis Preclinical Stage Products
10. Allergic Conjunctivitis Therapeutics Assessment
11. Allergic Conjunctivitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Allergic Conjunctivitis Key Companies
14. Allergic Conjunctivitis Key Products
15. Allergic Conjunctivitis Unmet Needs
16 . Allergic Conjunctivitis Market Drivers and Barriers
17. Allergic Conjunctivitis Future Perspectives and Conclusion
18. Allergic Conjunctivitis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=allergic-conjunctivitis-pipeline-2025-fda-approvals-therapies-clinical-trials-and-latest-developments-unveiled-by-delveinsight-bausch-lomb-inc-aldeyra-therapeutics-vanda-pharma-okyo-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma here
News-ID: 3999626 • Views: …
More Releases from ABNewswire

Apps4.Pro Migration Manager Transforms Microsoft 365 Tenant Migration: Zero Data …
Tirunelveli, India - 30 August, 2025 - When global enterprises need to migrate their Microsoft 365 environments, failure isn't an option. A single misstep can mean lost data, broken workflows, and frustrated teams. Today, Apps4.Pro-trusted by over 15,000 organizations worldwide-announces the enhanced Migration Manager platform that's redefining what's possible in tenant-to-tenant migration.
From Fortune 500 giants like Siemens Energy and Johnson & Johnson to fast-scaling startups, organizations are discovering a migration…

Dynamic Roofing Concepts Offers Roof Replacement in Brandon, FL as Aging Roofs I …
Brandon, FL - Homeowners in Brandon, Florida, are facing increased pressure to replace aging roofs as insurance companies tighten coverage requirements. Dynamic Roofing Concepts provides roof replacement in Brandon, FL [https://www.dynamicroofingconcepts.com/] and has seen increased demand as local homeowners face pressure from insurance companies to replace aging roofs.
In Florida, most homeowners are aware that old roofs are more vulnerable to wind and water damage. Insurance providers have responded by requiring…

How to Know When It's Time for an Exterminator: Evo Foam Pest Control's Expert G …
Not sure when to contact an exterminator? Evo Foam Pest Control explains the common signs of pest problems in Austin and why timely intervention is essential.
Austin, TX - Pest infestations can occur at any time, leaving homeowners in Austin, TX, wondering when it's necessary to call an exterminator Austin TX. With numerous pests, including ants, rodents, and termites, threatening the comfort of homes, it's essential to recognize the signs that…

Palm Coast Pest Control Shows How Eco-Friendly Pest Control Keeps Jupiter, FL Ho …
Discover how Palm Coast Pest Control uses eco-friendly solutions to protect Jupiter, FL homes from pests while maintaining a healthy, chemical-free environment.
Jupiter, FL - As residents of Jupiter, FL, seek effective and sustainable solutions to pest problems, Palm Coast Pest Control stands out as a trusted provider of eco-friendly pest control services. The company has earned a reputation for its commitment to keeping homes safe, healthy, and pest-free while also…
More Releases for Allergic
Prominent Allergic Rhinitis Market Trend for 2025: Advancements In Treating Nasa …
Which drivers are expected to have the greatest impact on the over the allergic rhinitis market's growth?
Anticipated growth in the allergic rhinitis market is predicted to be driven by increasing levels of air pollution and the impact of climate change. The term air pollution denotes the existence of harmful substances in our planet's atmosphere, which can negatively impact human health, damage the environment, and reduce the air's quality. Climate change…
Allergic Rhinitis: A Comprehensive Overview
Allergic rhinitis, commonly known as hay fever, is a condition where an individual's immune system overreacts to allergens in the air. These allergens, which may include pollen, dust, or pet dander, trigger inflammation inside the nose, leading to symptoms like sneezing, a runny nose, itchy eyes, and congestion. While often associated with the spring and fall seasons due to pollen levels, allergic rhinitis can affect individuals year-round, depending on the…
Allergic Conjunctivitis Market Statistics, Growth | Forecast
The new report published by The Business Research Company, titled ""Allergy Conjunctivitis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the allergy conjunctivitis market size has grown strongly in recent years. It will grow from $2.4 billion in 2023…
Anti-Allergic Drugs Market Overview 2030
Anti-allergic drugs represent a pivotal domain in healthcare, providing advanced solutions to alleviate symptoms triggered by allergens. With an ever-growing prevalence of allergies globally, the anti-allergic drugs market is witnessing a significant surge. Valued at USD 26,234 Million in 2021, the market is poised to skyrocket to USD 47,566 Million by 2030, showcasing a robust CAGR of 6.8%. In the United States alone, where allergies affect 40 to 50 million…
Allergic Conjunctivitis Market - Clear Eyes, Allergy-Free: Allergic Conjunctivit …
Newark, New Castle, USA: The "Allergic Conjunctivitis Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Allergic Conjunctivitis Market: https://www.growthplusreports.com/report/allergic-conjunctivitis-market/7892
This latest report researches the industry structure, sales, revenue,…
Allergic Conjunctivitis Market - Empowering Eyes, Enhancing Lives: Redefining Al …
Newark, New Castle, USA - new report, titled Allergic Conjunctivitis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Allergic Conjunctivitis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Allergic Conjunctivitis market. The report offers an overview of the market, which…